Profile
GHO Capital Partners LLP is a specialist healthcare investment advisor based in London. The firm focuses on unlocking high-growth opportunities in the healthcare sector by partnering with world-class leadership teams. With a team of over 80 members from diverse nationalities, GHO Capital leverages its global capabilities to drive better, faster, and more accessible healthcare solutions. The firm stands out due to its commitment to data-driven decision-making and strategic partnerships with ambitious management teams.
The firm primarily invests in the healthcare sector, covering a range of subsectors and themes, such as pharmaceuticals, medical devices, and healthcare services. GHO Capital's investment strategy includes targeting Series B through late-stage growth opportunities. The firm's geographic focus is transatlantic and global, with a significant presence in Europe and North America. GHO Capital manages a considerable amount of assets under management (AUM), with Fund IV raising over €2.5 billion.
Notable investments in GHO Capital's portfolio include Biocare Medical - a medical diagnostics company, Alcami - a pharmaceutical contract development and manufacturing organization, VISUfarma - an ophthalmic specialty pharmaceutical company, and Tjoapack - a contract packaging organization, illustrating their focus on high-growth healthcare businesses across different markets.
Industry
GHO Capital Partners LLP Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
Fund II
|
Fund of funds
|
Healthcare Services
SaaS
Software
MedTech
HealthTech
|
Seed
Series A
Series B
|
North America
Europe
|
$5-10 m
|
$975 M
|
November 2019
|
|
GHO Capital Fund III
|
Fund of funds
|
Healthcare Services
SaaS
Software
MedTech
Life Sciences
HealthTech
|
Seed
Series A
Series B
|
North America
Europe
|
$5-10 m
|
$2100 M
|
July 2021
|
|
GHO Capital IV LP
|
Fund of funds
|
Financial Services
Fintech
Healthcare Services
SaaS
Software
HealthTech
|
Seed
Series A
Series B
|
Europe
|
$5-10 m
|
$2500 M
|
October 2025
|
|
Healthcare Fund IV
|
Private Equity (PE)
|
Healthcare Services
Medical Devices
Pharmaceuticals
MedTech
HealthTech
|
Series B
Late Stage (Series C+)
|
North America
Europe
|
$50-100 m
|
—
|
September 2026
|
Contacts
Instant access on the web. Plans from $129/month — see pricing.